Axsome Therapeutics (AXSM) Total Non-Current Liabilities (2017 - 2026)

Axsome Therapeutics' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $585.3 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 29.24% year-over-year to $585.3 million; the TTM figure through Mar 2026 stood at $585.3 million (up 29.24% YoY), while the FY2025 annual figure was $524.0 million, up 24.81% from the prior year.
• Total Non-Current Liabilities came in at $585.3 million for Q1 2026 at Axsome Therapeutics, up from $524.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $585.3 million in Q1 2026 to a low of $136.0 million in Q2 2022.
• A 5-year average of $357.5 million and a median of $353.7 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities soared 120.05% in 2023 and advanced 24.81% in 2025, its largest moves.
• Axsome Therapeutics' Total Non-Current Liabilities stood at $190.8 million in 2022, then jumped by 69.77% to $324.0 million in 2023, then rose by 29.59% to $419.8 million in 2024, then rose by 24.81% to $524.0 million in 2025, then climbed by 11.7% to $585.3 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $585.3 million, $524.0 million, and $505.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison